BioSpace News Archive

An international collaboration between Bruce Power, Isogen and ITM Isotope Technologies Munich SE, announced the commencement of commercial production of lutetium-177.

Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced data from the late-breaker oral presentation of the Phase 3 trial of sabizabulin treatment for hospitalized adults with COVID-19 who required supplemental oxygen at IDWeek (Infectious Disease Week) 2022.

Motus GI Holdings, Inc. announced today that three abstracts featuring clinical data on the Pure-Vu EVS were presented in poster sessions at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held October 21 to 26, 2022 in Charlotte, North Carolina.

Softhread Inc. is pleased to announce an agreement with Clinical Consultants International (CCI), a wholly-owned subsidiary of Novo Integrated Sciences Inc., to offer a zero trust cybersecurity solution for smart and interconnected healthcare services consolidating its entrance into the rapidly evolving Health Care 4.0 ecosystem for health care delivery.

Taconic Biosciences has launched the FcResolv™ NOG portfolio, the first and only super immunodeficient mouse models lacking residual murine Fc gamma receptors known to confound results in antibody-based therapy studies.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka) announced today that long-term efficacy and safety data (final analysis up to Week 216) from the open-label extension of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the 27th International Hybrid Annual Congress of the World Muscle Society (WMS 2022) in Halifax, Nova Scotia, Canada.

TechsoMed, the developer of first of its kind AI Algorithm powered tissue viability imaging technology, announced today it has successfully completed patient enrollment in U.S. Pivotal trial designed to demonstrate the safety and effectiveness of its flagship product, BioTraceIO.

Amplifica Holdings Group, Inc., a privately-held, clinical-stage biopharmaceutical company announced it successfully closed an $11.8 million Series A Preferred Stock financing.